In silico directed evolution of Anabas testudineus AtMP1 antimicrobial peptide to improve in vitro anticancer activity
PeerJ · 2024
DOI: 10.7717/peerj.17894 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Shazrul Fazry und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Sciences, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antimicrobial Peptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Higher Education (MoHE), Malaysia, Universiti Kebangsaan Malaysia.
Abstract (Originalsprache)
Various studies have demonstrated that directed evolution is a powerful tool in enhancing protein properties. In this study, directed evolution was used to enhance the efficacy of synthesised Anabas testudineus AtMP1 antimicrobial peptides (AMPs) in inhibiting the proliferation of cancer cells. The modification of antimicrobial peptides (AMPs) and prediction of peptide properties using bioinformatic tools were carried out using four databases, including ADP3, CAMP-R3, AMPfun, and ANTICP. One modified antimicrobial peptide (AMP), ATMP6 (THPPTTTTTTTTTTTTTAAPARTT), was chosen based on its projected potent anticancer effect, taking into account factors such as amino acid length, net charge, anticancer activity score, and hydrophobicity. The selected AMPs were subjected to study in deep-learning databases, namely ToxIBTL and ToxinPred2, to predict their toxicity. Furthermore, the allergic properties of these antimicrobial peptides (AMPs) were verified by utilising AllerTOP and AllergenFP. Based on the results obtained from the database study, it was projected that antimicrobial peptides (AMPs) demonstrate a lack of toxicity towards human cells that is indicative of the broader population. After 48 hours of incubation, the IC 50 values of ATMP6 against the HS27 and MDA-MB-231 cell lines were found to be 48.03 ± 0.013 µg/ml and 7.52 ± 0.027 µg/ml, respectively. The IC 50 values of the original peptide ATMP1 against the MDA-MB-231 and HS27 cell lines were determined to be 59.6 ± 0.14 µg/ml and 8.25 ± 0.14 µg/ml, respectively, when compared. Furthermore, the results indicated that the injection of ATMP6 induced apoptosis in the MDA-MB-231 cell lines. The present investigation has revealed new opportunities for advancing novel targeted peptide therapeutics to tackle cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Food Sciences, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia.
- Faculty of Health and Life Sciences, INTI International University, Nilai, Negeri Sembilan, Malaysia.
- Dentistry Department, Al-Rafidain University College, Baghad, Iraq.
- Hangzhou Foreseebio Biotechnology Co., Ltd, Hangzhou, China.
- Department of Biomedical Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
- Jiangsu Vocational College of Medicine, Yancheng, China.
Förderung
- The Ministry of Higher Education (MoHE), Malaysia
- Universiti Kebangsaan Malaysia
Zitieren
APA
Fazry, S., Najm, A. A., Mahdi, I. M., Ang, A., Lee, L., Loh, C. T., Syed Alwi, S. S., Li, F., & Law, D. (2024). In silico directed evolution of Anabas testudineus AtMP1 antimicrobial peptide to improve in vitro anticancer activity. PeerJ. https://doi.org/10.7717/peerj.17894
Vancouver
Fazry S, Najm AA, Mahdi IM, Ang A, Lee L, Loh CT, et al. In silico directed evolution of Anabas testudineus AtMP1 antimicrobial peptide to improve in vitro anticancer activity. PeerJ. 2024. doi:10.7717/peerj.17894
BibTeX
@article{Fazry2024,
author = {Fazry, Shazrul and Najm, Ahmed Abdulkareem and Mahdi, Ibrahim Mahmood and Ang, Arnold and Lee, LiTing and Loh, Choy-Theng and Syed Alwi, Sharifah Sakinah and Li, Fang and Law, Douglas},
title = {In silico directed evolution of Anabas testudineus AtMP1 antimicrobial peptide to improve in vitro anticancer activity},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.17894}
}
EUVIMED